N-(3-chloro-4-cyanophenyl)methanesulfonamide | 53313-04-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-chloro-4-cyanophenyl)methanesulfonamide
• CAS: 53313-04-5
• 化学式: C₈H₇ClN₂O₂S
• mdl: MFCD01601850
• 分子量: 230.675
• InChiKey: SFGGYLRBEPTSDS-UHFFFAOYSA-N

物化性质

• 沸点：
  397.7±52.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  78.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-chloro-4-cyanophenyl)methanesulfonamide 在 lithium aluminium tetrahydride 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 乙腈 为溶剂， 反应 16.5h， 生成 TC-G 1008
  参考文献：
  名称：

  Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

  摘要：

  The identification of highly potent and orally bioavailable GPR39 agonists is reported. Compound 1, found in a phenotypic screening campaign, was transformed into compound 2 with good activity on both the rat and human GPR39 receptor. This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes. Thus, compound 3 is the first potent GPR39 agonist (EC(50)s <= 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.

  DOI：

  10.1021/ml500240d
• 作为产物：
  描述：

  2-氯-4-氨基苯腈 、 甲基磺酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以93%的产率得到N-(3-chloro-4-cyanophenyl)methanesulfonamide
  参考文献：
  名称：

  [EN] NOVEL SEH INHIBITORS AND THEIR USE
  [FR] NOUVEAUX INHIBITEURS DE SEH ET LEUR UTILISATION

  摘要：

  这项发明涉及新型sEH抑制剂及其在通过sEH酶介导的疾病治疗中的应用。具体来说，该发明涉及符合以下式I的化合物：其中R1、R2、R4、R5、R6、A、B、Y、Z、n和m如下所定义，并其药学上可接受的盐。该发明的化合物是sEH抑制剂，可用于通过sEH酶介导的疾病治疗，如高血压。因此，该发明进一步涉及包含该发明的化合物的药物组合物。该发明还进一步涉及使用该发明的化合物或包含该发明的药物组合物来抑制sEH并治疗与之相关的病症的方法。

  公开号：

  WO2009049157A1

文献信息

• [EN] NOVEL sEH INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE SEH ET LEUR UTILISATION
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009049154A1

  公开（公告）日：2009-04-16

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，该发明涉及符合下式I的化合物：其中R1、R2、R5a、R6a、A、B、Y、I和m如下所定义，以及其药学上可接受的盐。该发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，比如高血压。因此，该发明进一步涉及包括该发明的化合物的药物组合物。该发明还进一步涉及使用该发明的化合物或包括该发明的化合物的药物组合物来抑制sEH和治疗与之相关的病症的方法。
• Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles
  作者：Phuhai Nguyen、Nassima Oumata、Flavie Soubigou、Justine Evrard、Nathalie Desban、Pascale Lemoine、Serge Bouaziz、Marc Blondel、Cécile Voisset

  DOI：10.1016/j.ejmech.2014.05.083

  日期：2014.7

  Series of 6-aminophenanthridines and related heterocyclic compounds such as benzonaphtyridines were prepared. Reduction of one of the three aromatic rings was also performed. The compounds were first tested for their antiprion activity in a previously described yeast-based colourimetric prion assay. The most potent derivatives were then assayed ex vivo against the mammalian prion PrPSc in a cell-based

  制备了一系列6-氨基菲啶和相关的杂环化合物，例如苯并萘啶。还进行了三个芳环之一的还原。首先在先前描述的基于酵母的比色病毒测定中测试化合物的抗pr病毒活性。然后在基于细胞的测定中针对哺乳动物病毒PrP Sc离体测定最有效的衍生物。发现几种新化合物比母体铅6-氨基菲啶更有效。对抗酵母和哺乳动物pr病毒最有前景的化合物是8-叠氮基-6-氨基菲啶（3m）和7,10-二氢菲啶-6-胺（14）。在基于哺乳动物细胞的测定中，IC 50 这两种化合物的分别分别约为5μM和1.8μM。
• [EN] 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES<br/>[FR] DERIVES DE 1,2,4-OXADIAZOLE EN TANT QU'INHIBITEURS DE LA DIPEPTIDYLPEPTIDASE-IV DANS LE TRAITEMENT OU LA PREVENTION DE DIABETES
  申请人：MERCK & CO INC

  公开号：WO2005108382A1

  公开（公告）日：2005-11-17

  The present invention is directed to novel 1,2,4-oxadiazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新颖的1,2,4-噁二唑衍生物，这些衍生物是二肽基肽酶-IV酶（'DP-IV抑制剂'）的抑制剂，并且在治疗或预防涉及二肽基肽酶-IV酶的疾病方面具有用处，例如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及二肽基肽酶-IV酶的疾病方面的用途。
• 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Xu Jinyou

  公开号：US20080021009A1

  公开（公告）日：2008-01-24

  The present invention is directed to novel 1,2,4-oxadiazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及新型1,2,4-噁二唑衍生物，它们是二肽基肽酶-IV酶（“DP-IV酶”）的抑制剂，可用于治疗或预防涉及DP-IV酶的疾病，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的制药组合物，以及在涉及DP-IV酶的这些疾病的预防或治疗中使用这些化合物和组合物。
• NOVEL sEH INHIBITORS AND THEIR USE
  申请人：Ding Yun

  公开号：US20100210655A1

  公开（公告）日：2010-08-19

  The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及一种新型的sEH抑制剂及其在治疗由sEH酶介导的疾病中的应用。具体而言，本发明涉及式I的化合物：其中R1、R2、R5a、R6a、A、B、Y、I和m如下所定义，以及其药学上可接受的盐。本发明的化合物是sEH抑制剂，可用于治疗由sEH酶介导的疾病，如高血压。因此，本发明进一步涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物来抑制sEH和治疗与之相关的疾病的方法。